• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于降低肥胖症患者心血管代谢风险的胰高血糖素样肽-1受体激动剂——我们如何最好地描述其益处和价值？

GLP-1 RA for cardiometabolic risk reduction in obesity - How do we best describe benefit and value?

作者信息

Kumar Sant, Blaha Michael J

机构信息

MedStar Georgetown University Hospital, Washington, D.C. 20007, United States.

Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, MD 21287, United States.

出版信息

Am J Prev Cardiol. 2024 May 18;18:100682. doi: 10.1016/j.ajpc.2024.100682. eCollection 2024 Jun.

DOI:10.1016/j.ajpc.2024.100682
PMID:38840935
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11152602/
Abstract

How do we assess the overall benefit and value of GLP1-RAs? Current clinical trials often focus narrowly on individual atherosclerotic cardiovascular endpoints like MACE, potentially missing broader GLP-1 RA benefits across multiple comorbidities. Herein, we set out a framework for expanding outcome analyses in large trials that we believe will provide a more holistic understanding of GLP-1 RA benefits across the cardio-kidney-metabolic (CKM) spectrum, guiding patient care, guidelines, and insurance coverage decisions.

摘要

我们如何评估胰高血糖素样肽-1受体激动剂（GLP1-RAs）的总体益处和价值？当前的临床试验往往狭隘地聚焦于个别动脉粥样硬化性心血管终点，如主要不良心血管事件（MACE），可能会遗漏GLP-1 RA在多种合并症方面更广泛的益处。在此，我们提出了一个在大型试验中扩展结局分析的框架，我们认为这将提供对GLP-1 RA在心脏-肾脏-代谢（CKM）范围内益处的更全面理解，从而指导患者护理、指南制定以及保险覆盖范围决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe22/11152602/b19955b4ea61/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe22/11152602/b19955b4ea61/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe22/11152602/b19955b4ea61/gr1.jpg

相似文献

1
GLP-1 RA for cardiometabolic risk reduction in obesity - How do we best describe benefit and value?用于降低肥胖症患者心血管代谢风险的胰高血糖素样肽-1受体激动剂——我们如何最好地描述其益处和价值？
Am J Prev Cardiol. 2024 May 18;18:100682. doi: 10.1016/j.ajpc.2024.100682. eCollection 2024 Jun.
2
Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations.胰高血糖素样肽 1 受体激动剂（GLP-1 RAs）在非糖尿病患者中的潜在作用。
Cardiovasc Ther. 2022 Nov 16;2022:6820377. doi: 10.1155/2022/6820377. eCollection 2022.
3
Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?胰高血糖素样肽-1 受体激动剂与 2 型糖尿病患者的心血管风险降低：这是一类药物的作用吗？
Curr Cardiol Rep. 2018 Sep 26;20(11):113. doi: 10.1007/s11886-018-1051-2.
4
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists.肠促胰岛素的心血管作用：重点关注胰高血糖素样肽-1 受体激动剂。
Cardiovasc Res. 2023 May 2;119(4):886-904. doi: 10.1093/cvr/cvac112.
5
Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes.GLP-1 受体激动剂每周一次给药的有效性和耐受性：关注 2 型糖尿病中每周一次分子间的转换。
Front Endocrinol (Lausanne). 2022 Jul 15;13:892702. doi: 10.3389/fendo.2022.892702. eCollection 2022.
6
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.肥胖症且无糖尿病个体中胰高血糖素样肽-1 受体激动剂对体重和心血管代谢参数的疗效和安全性：系统评价和荟萃分析。
Endocr Pract. 2024 Feb;30(2):160-171. doi: 10.1016/j.eprac.2023.11.007. Epub 2023 Nov 27.
7
Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes.司美格鲁肽：新型每周一次 GLP-1RA 用于 2 型糖尿病。
Ann Pharmacother. 2018 Dec;52(12):1224-1232. doi: 10.1177/1060028018784583. Epub 2018 Jun 22.
8
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.GLP-1 受体激动剂在 2 型糖尿病治疗中的应用——最新进展。
Mol Metab. 2021 Apr;46:101102. doi: 10.1016/j.molmet.2020.101102. Epub 2020 Oct 14.
9
Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.用于治疗糖尿病肾病的 SGLT2 抑制剂和 GLP-1 受体激动剂的处方决策算法。
Clin J Am Soc Nephrol. 2020 Nov 6;15(11):1678-1688. doi: 10.2215/CJN.02690320. Epub 2020 Jun 9.
10
Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity.胰高血糖素样肽-1 受体激动剂在肥胖治疗中的应用。
Horm Res Paediatr. 2023;96(6):599-608. doi: 10.1159/000521264. Epub 2021 Dec 1.

引用本文的文献

1
The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes.在超重或肥胖且患有已确诊心血管疾病但无糖尿病的人群中，使用司美格鲁肽进行治疗所需的综合治疗人数。
Adv Ther. 2025 May;42(5):2513-2525. doi: 10.1007/s12325-025-03176-w. Epub 2025 Mar 29.
2
Health and Well-Being Coaching Adjuvant to GLP-1 Induced Weight Loss.健康与幸福指导辅助GLP-1诱导的体重减轻。
Am J Lifestyle Med. 2024 Nov 19:15598276241302273. doi: 10.1177/15598276241302273.
3
Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients.

本文引用的文献

1
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.司美格鲁肽与安慰剂治疗射血分数保留的肥胖相关性心力衰竭患者的比较：STEP-HFpEF和STEP-HFpEF DM随机试验的汇总分析
Lancet. 2024 Apr 27;403(10437):1635-1648. doi: 10.1016/S0140-6736(24)00469-0. Epub 2024 Apr 7.
2
FLOW trial stopped early due to evidence of renal protection with semaglutide.由于司美格鲁肽具有肾脏保护作用的证据，FLOW试验提前终止。
Eur Heart J Cardiovasc Pharmacother. 2024 Jan 5;10(1):7-9. doi: 10.1093/ehjcvp/pvad080.
3
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
胰高血糖素样肽 1 受体激动剂在心血管肿瘤学中的应用：癌症患者心代谢结局的病理生理学。
Int J Mol Sci. 2024 Oct 21;25(20):11299. doi: 10.3390/ijms252011299.
4
Detecting heart stress using NT-proBNP in patients with type 2 diabetes mellitus and hypertension or high-normal blood pressure: a cross-sectional multicentric study.使用 NT-proBNP 检测 2 型糖尿病伴高血压或血压正常高值患者的心脏应激：一项横断面多中心研究。
Cardiovasc Diabetol. 2024 Aug 12;23(1):297. doi: 10.1186/s12933-024-02391-z.
司美格鲁肽治疗射血分数保留的心力衰竭合并肥胖患者的疗效。
N Engl J Med. 2023 Sep 21;389(12):1069-1084. doi: 10.1056/NEJMoa2306963. Epub 2023 Aug 25.
4
The cardio-renal-metabolic connection: a review of the evidence.心肾代谢关联：证据回顾。
Cardiovasc Diabetol. 2023 Jul 31;22(1):195. doi: 10.1186/s12933-023-01937-x.
5
Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data.在 FOURIER 心血管结局试验中恢复依洛尤单抗治疗心血管疾病患者的死亡率数据：基于监管数据的重新分析。
BMJ Open. 2022 Dec 30;12(12):e060172. doi: 10.1136/bmjopen-2021-060172.
6
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.GLP-1 受体激动剂在 2 型糖尿病患者中的心血管、死亡率和肾脏结局：随机试验的系统评价和荟萃分析。
Lancet Diabetes Endocrinol. 2021 Oct;9(10):653-662. doi: 10.1016/S2213-8587(21)00203-5. Epub 2021 Aug 20.
7
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association.肥胖与心血管疾病：美国心脏协会科学声明
Circulation. 2021 May 25;143(21):e984-e1010. doi: 10.1161/CIR.0000000000000973. Epub 2021 Apr 22.
8
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.GLP-1 受体激动剂在 2 型糖尿病患者中的心血管、死亡率和肾脏结局：心血管结局试验的系统评价和荟萃分析。
Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785. doi: 10.1016/S2213-8587(19)30249-9. Epub 2019 Aug 14.
9
Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials.随机临床试验中首次事件时间和复发性事件方法的比较。
Circulation. 2018 Aug 7;138(6):570-577. doi: 10.1161/CIRCULATIONAHA.117.033065.
10
Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.从医疗体系和私人支付方的角度来看依洛尤单抗的最新成本效益评估： FOURIER 试验得出的见解。
JAMA Cardiol. 2017 Dec 1;2(12):1369-1374. doi: 10.1001/jamacardio.2017.3655.